1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      How I approach membrane lung dysfunction in patients receiving ECMO

      editorial

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction With improvements in circuit technology and expanding supportive evidence, extracorporeal membrane oxygenation (ECMO) use has grown rapidly over the past decade [1]. Advances in pump and membrane lung (ML) design have led to simpler and more efficient circuits. Circuit-related complications, however, remain frequent and associated with considerable morbidity [2]. Mechanisms of membrane lung dysfunction The ML is responsible for oxygen uptake and carbon dioxide removal. The non-biologic surface of the ML activates inflammatory and coagulation pathways with thrombus formation, fibrinolysis, and leukocyte activation [3–5] leading to ML dysfunction. Activation of coagulation and fibrinolysis can precipitate systemic coagulopathy or hemolysis, while clot deposition can obstruct blood flow [6, 7]. Additionally, moisture buildup in the gas phase and protein and cellular debris accumulation in the blood phase may contribute to shunt and dead-space physiology, respectively, impairing gas exchange [8, 9]. These three categories—hematologic abnormalities, mechanical obstruction, and inadequate gas exchange—prompt the majority of ML exchanges. Membrane lung monitoring Hematologic profile Monitoring of hematologic variables, including coagulation and hemolysis labs, can help identify the development of an ECMO coagulopathy or hemolysis. Pressure monitoring The pressure drop across the ML (ΔP) is measured as (Additional file 1: Supplemental Figure): \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\Delta P = P_{{{\text{Pre}}}} - P_{{{\text{Post}}}}$$\end{document} Δ P = P Pre - P Post where P Pre = pre-ML pressure, P Post = post-ML pressure. As clot forms in the ML, increases in resistance (R ML) are reflected as increases in ΔP. To correct for changes in blood flow rate (BFR), monitoring of ΔP normalized for BF rate (ΔP/BFR) more directly reflects R ML. Membrane lung gas transfer Applying the Fick principle across the ML, oxygen (O2) transfer may be calculated as: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$V^{\prime}{\text{O}}_{2} = {\text{BFR}}\left( {C_{{{\text{Post}}}} {\text{O}}_{2} {-}C_{{{\text{Pre}}}} {\text{O}}_{2} } \right)$$\end{document} V ′ O 2 = BFR C Post O 2 - C Pre O 2 where V′O2 = O2 transfer across the ML (mL/min), BFR = blood flow rate (L/min), C x O2 = O2 content of (pre-/post-ML) blood (mL/L) for \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$C_{x} {\text{O}}_{{2}} = {13}.{4} \cdot {\text{Hb}} \cdot S_{x} {\text{O}}_{{2}} + 0.0{3} \cdot P_{x} {\text{O}}_{{2}}$$\end{document} C x O 2 = 13.4 · Hb · S x O 2 + 0.03 · P x O 2 where Hb = hemoglobin (g/dL), S x O2 = O2 saturation of (pre-/post-ML) blood, P x O2 = O2 partial pressure of (pre-/post-ML) blood (mmHg). Measurement of V′O2 provides an objective measure of oxygen transfer and can confirm ML dysfunction, when clinically indicated. Membrane lung dysfunction Prompt recognition of ML dysfunction is vital for safety, allowing for elective replacement in a controlled manner. On the other hand, replacement of an adequately functioning device—requiring temporary cessation of ECMO support—places the patient at unnecessary risk while consuming a limited and expensive resource. Based on the pathophysiology of the ML, replacement may be required for one of three reasons: if there is (A) an associated hematologic abnormality, (B) an increasing obstruction to blood flow, or (C) inadequate gas exchange (Fig. 1). Fig. 1 Algorithmic approach to membrane lung monitoring for membrane lung dysfunction. Cut-off values for consideration of ML exchange are suggested values based on author experience and should be considered in the context of the patient and dependence on ECMO support. Please refer to text for details. ML, membrane lung; Plt, platelet count; INR, international normalized ratio; aPTT, activated partial thromboplastin time; fHb, free hemoglobin; LDH, lactate dehydrogenase; ΔP, Pressure drop across the ML; PPre, pre-ML pressure; PPost, post-ML pressure; R ML, resistance within the ML; BFR, blood flow rate; V′O2, membrane lung oxygen uptake; C PreO2, O2 content of pre-ML blood; C PostO2, O2 content of post-ML blood; P PreO2, partial pressure of pre-ML O2; P PostO2, partial pressure of post-ML O2; P PreCO2, partial pressure of pre-ML CO2; P PostCO2, partial pressure of post-ML CO2. Flowchart is designed with adult ECMO patients in mind and may not be applicable to pediatric or neonatal patients. *Extent and frequency of coagulation and hemolysis lab monitoring is not well-established and will vary by center. Not all labs are required to diagnose coagulopathy or hemolysis. **When a ML fails, we recommend considering switching the entire circuit, rather than just the ML, if: (a) the ML and pump head are fused; (b) the ML dysfunction occurs in the setting of circuit-related coagulopathy; or (c) the ML dysfunction occurs in the setting of an older circuit (i.e., longer than 2 weeks). While the first is due to technical limitation, the latter aim to reduce the risk of ongoing or new circuit-related coagulopathy in circuits at risk for this phenomenon Hematologic abnormalities The presence of an ECMO coagulopathy, typified by elevated clotting times, hypofibrinogenemia, thrombocytopenia, and elevated D-dimer without alternate explanation raises concern for circuit-related coagulopathy (CRC). Alternatively, evidence of hemolysis with elevated plasma-free hemoglobin, without alternate explanation, is concerning for circuit-related hemolysis. In both cases, the diagnosis is presumptive and only confirmed when values normalize after circuit exchange [6]. Obstruction to blood flow Increasing ΔP/BFR suggests increasing ML clot burden. As different MLs have different R ML, no cut-off values of ΔP define ML dysfunction and the trend should be carefully considered. A rapidly increasing ΔP, even if not associated with reduced gas exchange efficiency, is often a harbinger of impending ML failure and should prompt consideration of ML exchange. When ML pressures are not measured, an increasing pump speed requirement to maintain a stable BFR can serve as a surrogate for increasing ΔP, with the caveat that pump preload and afterload also affect this relationship. Inadequate oxygen uptake Worsening oxygenation during ECMO should prompt quantification of oxygen transfer. When the ML is no longer able to meet patient oxygen demand, ML exchange is indicated. There are three important considerations in making this decision. First, it is necessary that measured V′O2 is truly a maximal value. If circuit BFR is low, for example, the blood will be fully saturated early in the ML path and reserve will exist for additional oxygen transfer as BFR is increased. Similarly, if C PreO2 is artificially elevated, due to high recirculation fraction or impaired tissue extraction, or if the fraction of delivered oxygen in the sweep gas (FDO2) is below 100%, the gradient driving oxygen transfer is reduced, and measured V′O2 may not represent maximal capacity. As such, BFR should be sufficiently high that further increases do not increase arterial saturation, recirculation fraction should be minimized, and ML FDO2 set to 100% to ensure an accurate assessment of maximal V′O2. Second, though P Post-MLO2 less than 200 mmHg can suggest a failing ML [6], it is vital to calculate V′O2 for confirmation. In the setting of low C PreO2 or high circuit BFR, blood exiting the ML may not be fully saturated, with low P PostO2, despite normal V′O2. In this case, if the ML is exchanged, the patient is placed at risk without subsequent improvement in oxygen delivery. Finally, no absolute values diagnose inadequate oxygen transfer and clinical context is important. In general, however, in a patient with hypoxemia and a ML with maximal V′O2 < 100–150 mL/min, ML exchange is typically indicated. Inadequate carbon dioxide clearance ML dysfunction can also manifest as inadequate CO2 clearance. Calculation of V′CO2 is not typically performed as it varies in a nonlinear fashion with sweep gas flow rate and requires sampling ML exhaust CO2 [10]. However, persistent P Post-MLCO2 greater than 40 mmHg [6] and clearance of less than 10 mmHg PCO2 between pre- and post-ML blood gases despite sweep gas flow rates of 10 L/min or greater is suggestive of ML dysfunction and ML exchange should be considered. Sudden membrane lung failure While serial monitoring of the ML may identify markers of dysfunction and allow for elective exchange, acute ML failure is a potentially life-threatening event with unique considerations. Mechanisms to ensure optimal management are provided in the Additional file 2. Conclusion The decision to exchange a ML is complex and without clear guidelines. In this manuscript, we outline a physiologic approach to troubleshooting this common yet high risk event. Supplementary information Additional file 1. Membrane lung monitoring of pressure drop and oxygen transfer. Additional file 2. Sudden Membrane Lung Failure.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: not found

          Extracorporeal Life Support for Adults With Respiratory Failure and Related Indications

          The substantial growth over the last decade in the use of extracorporeal life support for adults with acute respiratory failure reveals an enthusiasm for the technology not always consistent with the evidence. However, recent high-quality data, primarily in patients with acute respiratory distress syndrome, have made extracorporeal life support more widely accepted in clinical practice.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Technical Complications during Veno-Venous Extracorporeal Membrane Oxygenation and Their Relevance Predicting a System-Exchange – Retrospective Analysis of 265 Cases

            Objectives Technical complications are a known hazard in veno-venous extracorporeal membrane oxygenation (vvECMO). Identifying these complications and predictive factors indicating a developing system-exchange was the goal of the study. Methods Retrospective study on prospectively collected data of technical complications including 265 adult patients (Regensburg ECMO Registry, 2009-2013) with acute respiratory failure treated with vvECMO. Alterations in blood flow resistance, gas transfer capability, hemolysis, coagulation and hemostasis parameters were evaluated in conjunction with a system-exchange in all patients with at least one exchange (n = 83). Results Values presented as median (interquartile range). Patient age was 50(36–60) years, the SOFA score 11(8–14.3) and the Murray lung injury Score 3.33(3.3–3.7). Cumulative ECMO support time 3411 days, 9(6–15) days per patient. Mechanical failure of the blood pump (n = 5), MO (n = 2) or cannula (n = 1) accounted for 10% of the exchanges. Acute clot formation within the pump head (visible clots, increase in plasma free hemoglobin (frHb), serum lactate dehydrogenase (LDH), n = 13) and MO (increase in pressure drop across the MO, n = 16) required an urgent system-exchange, of which nearly 50% could be foreseen by measuring the parameters mentioned below. Reasons for an elective system-exchange were worsening of gas transfer capability (n = 10) and device-related coagulation disorders (n = 32), either local fibrinolysis in the MO due to clot formation (increased D-dimers [DD]), decreased platelet count; n = 24), or device-induced hyperfibrinolysis (increased DD, decreased fibrinogen [FG], decreased platelet count, diffuse bleeding tendency; n = 8), which could be reversed after system-exchange. Four MOs were exchanged due to suspicion of infection. Conclusions The majority of ECMO system-exchanges could be predicted by regular inspection of the complete ECMO circuit, evaluation of gas exchange, pressure drop across the MO and laboratory parameters (DD, FG, platelets, LDH, frHb). These parameters should be monitored in the daily routine to reduce the risk of unexpected ECMO failure.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Current Understanding of How Extracorporeal Membrane Oxygenators Activate Haemostasis and Other Blood Components

              Extracorporeal membrane oxygenators are used in critical care for the management of severe respiratory and cardiac failure. Activation of the coagulation system is initiated by the exposure of blood to synthetic surfaces and the shear stresses of the circuit, especially from device pumps. Initial fibrinogen deposition and subsequent activation of coagulation factors and complement allow platelets and leucocytes to adhere to oxygenator surfaces and enhance thrombin generation. These changes and others contribute to higher rates of thrombosis seen in these patients. In addition, bleeding rates are also high. Primary haemostasis is impaired by platelet dysfunction and loss of their key adhesive molecules and shear stress causes an acquired von Willebrand defect. In addition, there is also altered fibrinolysis and lastly, administration of systemic anticoagulation is required to maintain circuit patency. Further research is required to fulyl establish the complexities of the haemostatic changes with these devices, and to elucidate the mechanistic changes that are mainly responsible so that plans can be made to reduce their complications and improve management.
                Bookmark

                Author and article information

                Contributors
                bzakhary@gmail.com
                Journal
                Crit Care
                Critical Care
                BioMed Central (London )
                1364-8535
                1466-609X
                30 November 2020
                30 November 2020
                2020
                : 24
                : 671
                Affiliations
                [1 ]GRID grid.5288.7, ISNI 0000 0000 9758 5690, Division of Pulmonary and Critical Care Medicine, , Oregon Health and Science University, ; Portland, OR USA
                [2 ]GRID grid.410569.f, ISNI 0000 0004 0626 3338, Department of Perfusion, , University Hospital Gasthuisberg, ; Leuven, Belgium
                [3 ]GRID grid.416653.3, ISNI 0000 0004 0450 5663, Department of Surgery, , Brooke Army Medical Center, ; San Antonio, TX USA
                [4 ]GRID grid.411482.a, General ICU, I° Department of Anesthesia and Intensive Care, , University Hospital of Parma, ; Parma, Italy
                [5 ]GRID grid.7548.e, ISNI 0000000121697570, Department of Biomedical, Metabolic, and Neural Sciences, , University of Modena and Reggio Emilia, ; Modena, Italy
                [6 ]GRID grid.5012.6, ISNI 0000 0001 0481 6099, Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), , Cardiovascular Research Institute Maastricht (CARIM), ; Maastricht, The Netherlands
                [7 ]GRID grid.413734.6, ISNI 0000 0000 8499 1112, Columbia University College of Physicians and Surgeons, , New York-Presbyterian Hospital, ; New York, USA
                [8 ]GRID grid.413734.6, ISNI 0000 0000 8499 1112, Center for Acute Respiratory Failure, , New York-Presbyterian Hospital, ; New York, NY USA
                Author information
                https://orcid.org/http://orcid.org/0000-0002-8662-5911
                Article
                3388
                10.1186/s13054-020-03388-2
                7704102
                33256824
                e81be291-5de8-4cbf-9776-e5bad4184f2f
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 14 September 2020
                : 13 November 2020
                Categories
                Editorial
                Custom metadata
                © The Author(s) 2020

                Emergency medicine & Trauma
                Emergency medicine & Trauma

                Comments

                Comment on this article